Quick Answer
Kiniksa Pharmaceuticals International, plc reported R&D Expense of $96.85 million for fiscal year 2025.
Kiniksa Pharmaceuticals International, plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $96.85M | -13.2% |
| 2024 | $111.62M | +46.7% |
| 2023 | $76.10M | +16.2% |
| 2022 | $65.49M | -34.0% |
| 2021 | $99.30M | -11.4% |
| 2020 | $112.04M | -17.0% |
| 2019 | $135.00M | +55.9% |
| 2018 | $86.60M | +53.7% |
| 2017 | $56.36M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.17M | -7.3% | +28.9% |
| June 30, 2025 | $18.75M | -21.9% | -3.0% |
| March 31, 2025 | $19.32M | -26.6% | -25.8% |
| September 30, 2024 | $26.06M | +52.3% | +8.5% |
| June 30, 2024 | $24.02M | +1.1% | -8.8% |
| March 31, 2024 | $26.33M | +73.6% | +53.9% |
| September 30, 2023 | $17.11M | +3.8% | -28.0% |
| June 30, 2023 | $23.77M | +72.2% | +56.7% |
- Kiniksa Pharmaceuticals International, plc showed a decrease of -13.2% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Kiniksa Pharmaceuticals International, plc’s r&d expense has grown by 71.9% (from $56.36 million to $96.85 million).
- The most recent figure is from Kiniksa Pharmaceuticals International, plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: